Boehringer Ingelheim extends PROTAC Discovery Program

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer AllianceBoehringer Ingelheim and University of Dundee achieve milestone in collaboration aimed at developing novel protein degradation medicinesResults published in Nature Chemical Biology showcase the use of the broadly applicable structure-based PROTAC design approach to discover highly potent and selective drug candidatesThe first PROTAC is made freely available via Boehringer Ingelheim ’s open innovation portal, opnMeStructure-based PROTAC design promises to accelerate the development of therapies against currently intractable cancer drivers 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news